A Study on the Expression of BCR-Abl Transcript in Mixed Phenotype Acute Leukemia (Mpal) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (Rt-Pcr) and Its Correlation With Hematological Remission Status Post Initial Induction Therapy

Bhatia, Prateek; Binota, Jogeshwar; Varma, Neelam; Bansal, Deepak; Trehan, Amita; Marwaha, Ram Kumar; Malhotra, Pankaj; Varma, Subhash

doi:10.4084/mjhid.2012.024

Cited by 9 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was not only consistent with other studies (Cetin et al, 2012;Ernst et al, 2012;Mu et al, 2012) but also a beneficial complement to other studies. It was reported in some early reports that m-bcr might be frequent in B lymphoid progenitor cells but uncommon in hematopoietic stem cells, explaining the rarity of m-bcr in CML but M-bcr and m-bcr per se can induce the myeloproliferative process, resulting in promotion of chronic phase CML (Bhatia et al, 2012;Gokbuget et al, 2012). These reports also showed that in patients showed a higher incidence of expression of m-bcr than M-bcr in ALL (Lee et al, 2005;Wang et al, 2011).…”

Section: 9961 Clinical Significance Of Bcr-abl Fusion Gene Subtypes mentioning

confidence: 88%

Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias

Zhou²,

Zhou³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (22), 9961-9966 IntroductionThe Philadelphia chromosome (Ph), t (9; 22) (q34; q11.2) is transcribed into a fusion gene, BCR-ABL (Awan et al., 2012;Sabir et al., 2012). This translocation is one of the most common genetic abnormalities detected in leukemia. The site of the breakpoint in the BCR gene may influence the phenotype of diseases. In the vast majority of patients, the breakpoints in the BCR gene are clustered within three well-defined regions: (I) a 55 kb sequence of the first intron, called the minor breakpoint cluster region (m-bcr); (II) a 5.8 kb region spanning exons 12-16, called the major breakpoint cluster region (M-bcr), and finally; (III) intron 19, called μ-bcr. The resultant fusion transcript (e1-a2) (m-bcr) encodes a 190 kDa chimeric protein (p190), and in cases of M-bcr, codes a 210 kDa chimeric protein (p210) and in cases of μ-bcr, a 230 kDa protein (p230) (Fausel, 2007). Large studies indicated that BCR-ABL fusion gene is a highly useful diagnostic tool that controls the effectiveness of the chronic myelogenous

show abstract

Section: 9961 Clinical Significance Of Bcr-abl Fusion Gene Subtypes mentioning

confidence: 88%

Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias

Zhou²,

Zhou³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Using the WHO 2008 criteria, MPAL shows a lower frequency (0·5–2·8%) compared to EGIL system (2–5%), indicating that the number of patients encompassed in this new MPAL category is significantly lower (Al‐Seraihy et al , ; Atfy et al , ; Matutes et al , ; Bhatia et al , ; Yan et al , ). MPAL affects both adults and children (including infants) and shows a male predominance.…”

Section: Egil Scoring System For Balmentioning

confidence: 99%

“…Cytogenetic abnormalities are very common in ALAL. Cytogenetic analysis reveals clonal chromosomal abnormalities in 59–91% of patients with MPAL (Lee et al , ; Al‐Seraihy et al , ; Gerr et al , ; Atfy et al , ; Matutes et al , ; Bhatia et al , ; Yan et al , ) and in 80–90% of patients with AUL (Cuneo et al , ; Heesch et al , ). Clonal chromosome abnormalities are numerical (involving changes in chromosome number), structural (including mainly translocations and deletions) or both numerical and structural.…”

Section: The Significance Of Cytogenetics In Alalmentioning

confidence: 99%

“…However, in another study including only 4 MPAL patients the BCR‐ABL1 transcript type in adult cases was b3a2 (p210) in 2/3 of cases and e1a2 (p190) in 1/3 of cases. The single paediatric patient was positive for b3a2 transcript (Bhatia et al , ). In a recent study IKZF1 deletions were found exclusively in 50% of patients with t(9;22)(q34;q11.2)/ BCR‐ABL1 fusion and B+M phenotype without significant difference on OS between patients with and without gene mutations (Yan et al , ).…”

Section: Cytogenetic Changes Associated With Mpal And/or Balmentioning

confidence: 99%

See 1 more Smart Citation

Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview

Manola

2013

Br J Haematol

View full text Add to dashboard Cite

Summary Acute leukaemia of ambiguous lineage (ALAL) is a rare complex entity with heterogeneous clinical, immunophenotypic, cytogenetic and molecular genetic features and adverse outcome. According to World Health Organization 2008 classification, ALAL encompasses those leukaemias that show no clear evidence of differentiation along a single lineage. The rarity of ALAL and the lack of uniform diagnostic criteria have made it difficult to establish its cytogenetic features, although cytogenetic analysis reveals clonal chromosomal abnormalities in 59–91% of patients. This article focuses on the significance of cytogenetic analysis in ALAL supporting the importance of cytogenetic analysis in the pathogenesis, diagnosis, prognosis, follow up and treatment selection of ALAL. It reviews in detail the types of chromosomal aberrations, their molecular background, their correlation with immunophenotype and age distribution and their prognostic relevance. It also summarizes some novel chromosome aberrations that have been observed only once. Furthermore, it highlights the ongoing and future research on ALAL in the field of cytogenetics.

show abstract

“…Leukemic cells of MPAL have features of both myeloid and lymphoid lineage, and MPAL comprises 0.5-3% of all acute leukemias (2)(3)(4)(5). In the 2008 WHO criteria, MPAL was classified into five subtypes, and Philadelphia chromosome positive (Ph+) MPAL accounts for 20-40% of MPAL (2,3,6). Although the prognosis of Ph+MPAL is poor, there is no consensus on the optimal treatment for Ph+ MPAL (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone

et al. 2016

View full text Add to dashboard Cite

Philadelphia chromosome positive (Ph+) mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia having both myeloid and lymphoid features for which no optimal treatment has yet been established. We herein describe two elderly Ph+MPAL patients who achieved molecular remission without any serious adverse events by treatment with dasatinib and prednisolone. Although dasatinib induction therapy combined with prednisolone is known to be a highly effective treatment for Ph+ acute lymphoblastic leukemia, its efficacy for Ph+MPAL has not been shown. The clinical courses of the present cases suggest that combination therapy with dasatinib and prednisolone is a safe and effective therapeutic modality in elderly Ph+ MPAL patients.

show abstract

A Study on the Expression of BCR-Abl Transcript in Mixed Phenotype Acute Leukemia (Mpal) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (Rt-Pcr) and Its Correlation With Hematological Remission Status Post Initial Induction Therapy

Cited by 9 publications

References 12 publications

Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias

Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias

Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview

Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone

Contact Info

Product

Resources

About